Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024.

Revenue
+8.91%
EPS
+115.3%
Free cash flow
+2.72%

Quarter to September 2026, against a year earlier

34.84 0.47 +1.37%
Market cap
$2.6B
P/E
30.1×
Fwd P/E
26.4×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 77.42 68.04 92.70 56.38 28.75 37.22
Piotroski F-Score
— — 4 5 5 6 7 6 8
Altman Z-Score
— — 10.89 26.69 27.56 12.65 13.03 8.34 8.89
P/S ratio
0.62 0.62 2.48 10.54 8.96 3.58 3.25 1.27 1.71
P/FCF ratio
16.55 16.55 0.00 103.33 187.66 36.55 19.09 8.52 11.47
Altman Z″-Score (non-manufacturers)
(12.83) (10.46) 5.49 4.27 6.00 6.15 7.74 7.20 7.14
Beneish M-Score
— (2.53) (1.70) (1.33) (1.22) (2.38) (3.23) (3.33) (3.45)
P/Operating CF
20.26 20.26 (103.69) 555.88 508.96 54.74 93.89 28.38 40.58
P/B ratio
0.00 0.00 4.98 21.77 17.82 7.48 6.39 3.51 4.26
EV/Sales
0.60 0.60 2.15 10.23 8.73 3.35 2.91 1.08 1.47
EV/EBITDA
11.60 11.60 41.79 344.18 129.96 105.67 49.16 17.80 20.99
EV/FCF
16.15 16.15 (109.92) 100.36 182.86 34.16 17.12 7.24 9.88
Current Ratio
0.94 0.81 3.66 2.45 2.62 2.72 3.44 2.80 2.73
Net Debt/EBITDA
(0.05) (0.08) (6.81) (10.66) (3.55) (7.59) (5.76) (3.23) (3.44)
Debt/Equity
(0.05) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
13.98% (0.69%) (89.47%) 33.04% 31.41% 9.66% 13.34% 11.14% 12.48%
ROA
(35.31%) 1.73% (8.94%) 22.98% 21.49% 6.74% 9.55% 7.97% 8.67%
ROIC
0.00% 0.00% 17.85% 9.05% 15.27% 7.77% 21.31% 21.72% 25.88%
Return on Tangible Assets
3,341.94% (13.52%) (8.62%) 40.11% 39.92% 10.74% 13.35% 17.17% 15.43%
Average Days of Receivables
85.44 80.77 74.78 80.08 98.10 111.35 81.10 73.59 62.39
Earnings Yield
(3.26%) (3.26%) (1.41%) 1.29% 1.47% 1.08% 1.77% 3.48% 2.69%
Free Cash Flow Yield
6.04% 6.04% (0.79%) 0.97% 0.53% 2.74% 5.24% 11.73% 8.72%
Free Cash Flow per Share
(1.78) 0.31 (0.22) 0.41 0.27 0.84 1.95 1.90 2.24
Book value per Share
(17.19) (17.17) 5.51 1.95 2.83 4.09 5.82 4.61 6.02
Free Cash Flow
(10.09) 1.69 (4.49) 35.17 23.91 77.15 185.17 173.70 191.78
EV/EBIT
14.62 14.62 51.00 422.77 135.18 112.92 50.97 18.63 22.21
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026